Menlo Ventures hires Greg Yap

| October 11, 2017 | 0 Comments

greg yapCourtesy Menlo Ventures

Menlo Ventures, a Silicon Valley venture firm, just hired a
partner to lead its investments in biotech and life

The firm, which has $5 billion under management, hired Greg Yap,
a life science veteran who has spent 20 years in the

Yap will help Menlo find companies to invest in that are “at the
intersection of biology and computer science,” Yap told Business

As part of its push back into biotech, the firm will be
devoting 15% of its latest $450
million fund
to companies in that space.Â

Founded in 1976, Menlo has in the past invested in life sciences
companies including Gilead Sciences — a biotech that now has a
$107 billion market cap — but has over the past few decades
focused its investments into tech companies, including Uber,
Betterment, and Warby Parker.Â

Menlo partner Mark Siegel told Business Insider that the firm
originally got out of biotech investing in the 90s because the
timeline of bringing a drug from discovery to approval was too
long for returns, especially compared to the growing IT industry.
Siegel said that’s not the case now, especially in the main areas
Menlo will be investing in.

Specifically, the plan will be to invest in companies that are in
diagnostics, genomics, digital health, synthetic biology, and
have a data-driven platforms for drug discovery. So
far, Menlo has invested in Synthego, Cofactor Genomics, Clear
Labs, Recursion Pharmaceuticals, and
3T Biosciences
, a startup also reportedly backed by Peter
Thiel and Sean Parker.Â

Yap spent his career working at companies such as Illumina
Ventures, Roche, and Affymetrix. Joining the Menlo team, he’ll be
bringing along his experience working as both an entrepreneur and
in the day-to-day operations of the companies navigating
regulatory processes and other things traditional technology
companies might not encounter.

Yap said he’s looking to invest in “iconic entrepreneurs,” though
they don’t necessarily have to be based in Silicon Valley.Â

Source Article

Category: News

About the Author ()